We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+22.3%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$455M
AUM Growth
+$90.7M
(+25%)
Cap. Flow
+$33.6M
Cap. Flow
% of AUM
7.38%
Top 10 Holdings %
Top 10 Hldgs %
56.91%
Holding
55
New
3
Increased
34
Reduced
5
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$15.3M |
| 2 |
SHPG
Shire pic
SHPG
|
+$13.8M |
| 3 |
NeoGenomics
NEO
|
+$7.39M |
| 4 |
NVTR
Nuvectra Corporation Common Stock
NVTR
|
+$4.2M |
| 5 |
Harvard Bioscience
HBIO
|
+$3.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ENTL
Entellus Medical, Inc. Common Stock
ENTL
|
+$16.4M |
| 2 |
Nektar Therapeutics
NKTR
|
+$4.44M |
| 3 |
BLUE
bluebird bio
BLUE
|
+$2.44M |
| 4 |
QuidelOrtho
QDEL
|
+$2.04M |
| 5 |
Codexis
CDXS
|
+$1.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.88% |
| 2 | Communication Services | 4.24% |
| 3 | Energy | 0.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
NeoGenomics
NEO
$1.96B
| $38.8M | 8.53% |
4,760,332
+912,730
| +24% | +$7.39M |
|
|
2
Nektar Therapeutics
NKTR
$2.39B
| $31.9M | 7% |
20,006
-3,443
| -15% | -$4.44M |
|
|
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
| $27.3M | 6% |
1,675,148
+108,344
| +7% | +$1.74M |
|
|
4
Harvard Bioscience
HBIO
$27.5M
| $27.2M | 5.97% |
544,129
+80,264
| +17% | +$3.6M |
|
|
SHPG
5
DELISTED
Shire pic
SHPG
| $26.9M | 5.9% |
179,976
+100,369
| +126% | +$13.8M |
|
6
AtriCure
ATRC
$1.92B
| $24M | 5.26% |
1,167,672
+92,225
| +9% | +$1.67M |
|
|
7
Tandem Diabetes Care
TNDM
$1.34B
| $23.5M | 5.16% |
+4,734,238
| New | +$15.3M |
|
8
Xencor
XNCR
$1.5B
| $20.9M | 4.59% |
697,756
+52,992
| +8% | +$1.39M |
|
|
MODN
9
DELISTED
MODEL N, INC.
MODN
| $19.3M | 4.24% |
1,070,023
+125,898
| +13% | +$2.1M |
|
10
Ligand Pharmaceuticals
LGND
$5.76B
| $19.3M | 4.24% |
187,243
+7,753
| +4% | +$767K |
|
|
IMMU
11
DELISTED
Immunomedics Inc
IMMU
| $14.9M | 3.27% |
1,019,920
+75,516
| +8% | +$1.23M |
|
12
Omnicell
OMCL
$1.61B
| $14.7M | 3.22% |
338,113
+20,782
| +7% | +$955K |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $14.5M | 3.17% |
166,744
+10,840
| +7% | +$875K |
|
14
Heron Therapeutics
HRTX
$93.9M
| $13.1M | 2.87% |
473,275
+59,554
| +14% | +$1.35M |
|
|
CSII
15
DELISTED
Cardiovascular Systems, Inc.
CSII
| $10.3M | 2.26% |
469,687
+25,683
| +6% | +$617K |
|
16
Halozyme
HALO
$9.79B
| $9.85M | 2.16% |
503,029
+35,383
| +8% | +$685K |
|
|
DVAX
17
DELISTED
Dynavax Technologies
DVAX
| $9.01M | 1.98% |
453,634
+38,061
| +9% | +$657K |
|
18
Globus Medical
GMED
$10.7B
| $8.93M | 1.96% |
179,264
+2,807
| +2% | +$132K |
|
|
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $7.8M | 1.71% |
626,585
+29,807
| +5% | +$363K |
|
|
XENT
20
DELISTED
Intersect ENT, Inc
XENT
| $7.44M | 1.63% |
189,231
+10,335
| +6% | +$378K |
|
|
21
Codexis
CDXS
$151M
| $6.97M | 1.53% |
633,665
-170,559
| -21% | -$1.63M |
|
22
Bio-Techne
TECH
$11.2B
| $5.84M | 1.28% |
154,620
+2,336
| +2% | +$82.5K |
|
23
HealthStream
HSTM
$819M
| $5.5M | 1.21% |
221,668
+12,081
| +6% | +$290K |
|
|
NVTR
24
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $5.39M | 1.18% |
+413,646
| New | +$4.2M |
|
|
KTWO
25
DELISTED
K2M Group Holdings, Inc
KTWO
| $5.21M | 1.14% |
275,068
+4,310
| +2% | +$85.4K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q1 2018 Portfolio in Review
As of Q1 2018, First Light Asset Management held 55 positions worth $455M, up 25% from $365M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
First Light Asset Management deployed $33.6M of net new capital in Q1 2018, opening 3 new positions and adding to 34 existing holdings. Its largest new stake was Tandem Diabetes Care: 4,734,238 shares worth $23.5M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 84% a quarter earlier, followed by Communication Services and Energy.
On the sell side, the largest reduction was Nektar Therapeutics, an estimated $4.44M trimmed.
- First Light Asset Management's largest Q1 2018 buy was Tandem Diabetes Care: 4,734,238 shares worth $23.5M.
- First Light Asset Management added most to Shire pic in Q1 2018, an estimated $13.8M increase.
- First Light Asset Management's biggest Q1 2018 reduction was Nektar Therapeutics, cutting an estimated $4.44M.
- First Light Asset Management fully exited Entellus Medical, Inc. Common Stock in Q1 2018, selling an estimated $16.4M.
- First Light Asset Management's ten largest holdings make up 57% of its $455M portfolio in Q1 2018.
- First Light Asset Management opened 3 new positions and closed 3 in Q1 2018.
- First Light Asset Management's portfolio value rose 25% quarter-over-quarter to $455M.
Based on First Light Asset Management's 13F filing for Q1 2018, filed 15 May 2018.